Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort.
Clairelyne DupinDrifa BelhadiLaurent GuilleminaultAnne-Sophie GamezPatrick BergerFrédéric De BlayPhilippe BonniaudChristophe LeroyerGuillaume MahayPierre-Olivier GirodetChantal RaherisonStéphanie FryGeneviève Le BourdellèsAlain ProustLise RosencherGilles GarciaArnaud BourdinCécile ChenivesseAlain DidierCamille CouffignalCamille TailléPublished in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2020)
In this first real-life cohort study of predominantly steroid-dependent SA, dupilumab significantly improved asthma control and lung function and reduced oral steroids use and exacerbations rate. Despite limitations due to the retrospective study, these results are consistent with controlled trials efficacy data. Further studies are required to assess the clinical significance and long-term prognosis of sustained dupilumab-induced hypereosinophilia.